J. Reagan

发表

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.

J. Castillo, J. Reagan, 2014, Future oncology.

Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia

J. Castillo, J. Reagan, 2011, Expert review of anticancer therapy.

Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies.

J. Mitri, J. Castillo, Jorge J Castillo, 2012, Blood.

or Monocyte-Derived Dendritic Cells Cross-Priming, Than Do Dermal-Interstitial by Either Single Peptide Presentation or Activity in the Absence of Bioactive IL-12p70, Stimulate Greater Cytolytic T Lymphocyte Hematopoietic Progenitors + from CD34 Mature Human Langerhans Cells Derived

James W. Young, C. Münz, T. Dao, 2004 .

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.

K. Busam, G. Heller, James W. Young, 2003, Blood.

Preliminary findings regarding the use of direct oral anticoagulants in cerebral venous thrombosis

J. Reagan, Andrew Hsu, Hetal M Mistry, 2020, Clinical Neurology and Neurosurgery.

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL

E. Winer, J. Butera, A. Nadeem, 2011, Cancer Chemotherapy and Pharmacology.

observational studies in patients with diabetes mellitus type 2: a meta-analysis of Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma

J. Mitri, J. Castillo, J. Reagan, 2012 .

Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses1

M. Sadelain, G. Heller, James W. Young, 2005, The Journal of Immunology.

Cellular immunotherapy for refractory hematological malignancies

J. Butera, P. Quesenberry, H. Safran, 2013, Journal of Translational Medicine.

Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells

P. Quesenberry, J. Reagan, L. Fast, 2013 .

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma

J. Butera, D. Treaba, A. Chorzalska, 2021, Blood Advances.

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells.

G. Heller, James W. Young, C. Münz, 2005, The Journal of Immunology.

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study

J. Butera, J. Reagan, A. Olszewski, 2022, The oncologist.

Refractoriness to red blood cell transfusion therapy due to hypersplenism

I. Sahin, J. Reagan, J. Sweeney, 2018, Transfusion.

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

J. Reagan, A. Olszewski, Andrew Hsu, 2020, Thrombosis Research.

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia

J. Reagan, P. Egan, 2018, OncoTargets and therapy.

Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy

Annette S. Kim, J. Butera, P. Quesenberry, 2019, British journal of haematology.

Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record.

Ross W Hilliard, J. Reagan, A. Olszewski, 2020, Rhode Island medical journal.

Cytolytic T + Inducing Antigen-Specific CD 8 Peptide-Pulsed Langerhans Cells for Progenitors Are More Potent Than Hemopoietic + Modified Human CD 34 Langerhans Cells Derived from Genetically

Young, M. Sadelain, W. James, 2004 .

IgM myeloma: A multicenter retrospective study of 134 patients

R. Vij, J. Laubach, P. Richardson, 2017, American journal of hematology.

Antibiotic use during cytarabine consolidation in acute myeloid leukemia

D. Farmakiotis, J. Reagan, P. Egan, 2020, Annals of Hematology.

Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

P. Quesenberry, O. Liang, C. Ventetuolo, 2019, Clinical lymphoma, myeloma & leukemia.

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells

J. Reagan, L. Fast, M. Nevola, 2018, Experimental Hematology & Oncology.

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia

J. Butera, F. Claas, P. Quesenberry, 2015, Blood Cancer Journal.

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis

Thalia Shoshana Field, K. Furie, G. Tsivgoulis, 2022, Stroke.

Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality.

J. Castillo, J. Reagan, A. Pham, 2013, Leukemia research.

Plasmablastic Lymphoma: A Systematic Review

J. Castillo, J. Reagan, 2011, TheScientificWorldJournal.

Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia

J. Reagan, A. Olszewski, B. Bakow, 2020, Supportive Care in Cancer.

Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia

J. Reagan, A. Zayac, 2021, Hemato.

Why is my patient neutropenic?

J. Castillo, J. Reagan, 2012, Hematology/oncology clinics of North America.

Tumor Derived Extracellular Vesicles Modulate Gene Expression in T Cells.

J. Reagan, L. Fast, C. Schorl, 2022, Gene.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage

P. Quesenberry, M. Dooner, Sicheng Wen, 2013 .

Pruritic Rash in a Patient with Hodgkin's Lymphoma

D. Farmakiotis, J. Reagan, A. Le, 2018, Cureus.

Murine Leukemia-Derived Extracellular Vesicles Elicit Antitumor Immune Response

A. Chorzalska, P. Dubielecka, Sicheng Wen, 2021, Journal of blood medicine.

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies

J. Butera, P. Quesenberry, H. Safran, 2012, Advances in hematology.

Dysuria in a Patient With Aids and Lymphoma

D. Farmakiotis, J. Reagan, L. Pisharodi, 2017 .

G. Heller, James W. Young, C. Münz, 2004, The Journal of Immunology.

Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles

W. LaFrance, P. Quesenberry, G. Camussi, 2019, Journal of cellular physiology.

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

J. Castillo, W. Sikov, J. Reagan, 2015, British journal of haematology.

Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies

J. Castillo, J. Reagan, K. Bishop, 2014, British journal of haematology.

Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83.

James W. Young, B. Sénéchal, J. Reagan, 2004, Blood.

Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?

Seah H. Lim, J. Reagan, L. Fast, 2017, Leukemia & lymphoma.

Adoptive immunotherapy for myeloid malignancies.

J. Reagan, 2014, Leukemia supplements.

Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.

Ariel Birnbaum, Carolyn R. Bartley, K. Perez, 2016, Journal of oncology practice.

Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies

Shaolei Lu, J. Reagan, A. Olszewski, 2022, Cancer.

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia

Peng Zhang, N. Ahsan, P. Gruppuso, 2018, Molecular oncology.

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day‐14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease

J. Butera, P. Quesenberry, M. Quesenberry, 2018, Clinical lymphoma, myeloma & leukemia.

Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.

J. Castillo, F. Lansigan, J. Reagan, 2015, Leukemia research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas

J. Reagan, A. Olszewski, T. Ollila, 2018, British journal of haematology.

Outcomes of bendamustine‐ or cyclophosphamide‐based first‐line chemotherapy in older patients with indolent B‐cell lymphoma

J. Butera, J. Castillo, J. Reagan, 2019, American journal of hematology.

Cancer Stem Cells: A Matter of Perspective

P. Quesenberry, B. Ramratnam, J. Reagan, 2013 .

Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response‐specific osteo‐mesenchymal profiles

J. Butera, P. Quesenberry, M. Castillo-Martin, 2022, British journal of haematology.

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Jeffrey A Jones, Sonali M. Smith, A. LaCasce, 2021, Blood.

Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma

S. Giri, J. Reagan, A. Olszewski, 2020, American journal of hematology.

Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies.

J. Mitri, J. Castillo, A. Zarrabi, 2012, Leukemia research.

Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia

J. Reagan, A. Olszewski, Peter Barth, 2019, Blood.

Marrow cell genetic phenotype change induced by human lung cancer cells.

P. Quesenberry, M. Dooner, B. Ramratnam, 2011, Experimental hematology.

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

R. Zini, P. Quesenberry, N. Ahsan, 2018, Blood.

Bone marrow – speci fi c loss of ABI 1 induces myeloproliferative neoplasm with features resembling human myelo fi brosis

R. Zini, P. Quesenberry, N. Ahsan, 2018 .

Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies.

J. Mitri, J. Castillo, M. Furman, 2014, Clinical lymphoma, myeloma & leukemia.

Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base

J. Reagan, A. Olszewski, T. Ollila, 2019, Leukemia & lymphoma.

Mechanisms of Hypercalcemia in Non‐Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review

J. Reagan, R. Shallis, Rachel S Rome, 2017, Clinical lymphoma, myeloma & leukemia.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

J. Castillo, M. Gilbertson, T. Tousseyn, 2019, British journal of haematology.

Extracellular vesicles in leukemia.

P. Quesenberry, J. Reagan, L. Fast, 2018, Leukemia research.

Acquired Syphilis With Anemia and Leukoerythroblastic Reaction: A Case Report

J. Reagan, Mark P Legolvan, K. Mantripragada, 2016, Annals of Internal Medicine.

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Ming-Yu Liu, Fei Li, D. Blaise, 2023, Heliyon.

The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.

J. Reagan, Peter Barth, C. Vale, 2018, Future oncology.

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl induced leukemia

E. Winer, V. Falanga, D. Treaba, 2014, Leukemia.

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

J. Dipersio, J. Griffin, A. Azab, 2021, Leukemia & lymphoma.

Primary refractory Hodgkin lymphoma: Limited options and poor survival—but not always

J. Castillo, J. Reagan, E. Winer, 2014, American journal of hematology.

Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma

J. Reagan, A. Olszewski, Peter Barth, 2019, Cancer medicine.

The Relationship Between Obesity and Lymphoma: A Meta-Analysis of Prospective Cohort Studies

J. Mitri, J. Castillo, A. Zarrabi, 2011 .

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study

J. Reagan, A. Olszewski, Peter Barth, 2023, The oncologist.

P. Quesenberry, G. Camussi, M. Dooner, 2019, Neural regeneration research.

Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study†

O. Panagiotou, Mengyang Di, J. Reagan, 2020, Leukemia & lymphoma.

Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B‐cell lymphomas

J. Castillo, J. Reagan, A. Olszewski, 2018, American journal of hematology.

Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections

D. Farmakiotis, J. Reagan, Andrew Hsu, 2020, Supportive Care in Cancer.

Choice of anticoagulation in patients with low risk antiphospholipid syndrome

J. Reagan, A. Olszewski, B. Bakow, 2023, Journal of Thrombosis and Thrombolysis.

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Sonali M. Smith, A. LaCasce, J. Leonard, 2017 .

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

J. Reagan, Adel Chergui, 2023, Cancers.

Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

P. Quesenberry, O. Liang, C. Ventetuolo, 2019, Clinical lymphoma, myeloma & leukemia.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Advances in cellular therapy for the treatment of leukemia.

P. Quesenberry, J. Reagan, Kalyan C Mantripragada, 2014, Discovery medicine.

Why is my patient neutropenic?

J. Castillo, J. Reagan, 2012, Hematology/oncology clinics of North America.

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

D. Treaba, A. Chorzalska, P. Dubielecka, 2014, Leukemia supplements.

Plasmablastic Lymphoma: A Systematic Review

J. Castillo, J. Reagan, 2011, TheScientificWorldJournal.

Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.

J. Castillo, F. Lansigan, J. Reagan, 2015, Leukemia research.

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Jeffrey A Jones, Sonali M. Smith, A. LaCasce, 2018, Blood.